Figure 4.

The IL-36 receptor is preferentially expressed by plasmacytoid dendritic cell s. (a–e) Representative flow cytometry plots showing IL36R surface expression compared with fluorescence minus one control. (a) neutrophils (gated as CD14⁺, CD15⁺, CD16⁺ cells); (b) innate lymphoid cells (lineage^- [CD3^-, CD4^-, CD19^-, CD20^-, CD56^-], CD127⁺); (c) monocytes (CD3^-, CD20^-, CD19^-, CD56^-) separated into classical (CD16^-, CD14^high), intermediate (CD16⁺, CD14⁺), and pro-inflammatory (CD16^high, CD14^-) populations; (d) pDCs (lineage^-, HLA-DR⁺, CD123⁺, CD11c^-) and mDCs (lineage^-, HLA-DR⁺, CD123^-, CD11c⁺). (e) Histogram showing the percentage IL36R⁺ cells in each leukocyte population. Data were obtained in at least three GPP cases and three sex-matched controls. Results are presented as mean ± SEM. No significant differences were observed between GPP cases and healthy donors. FMO, fluorescence minus 1; IL36R, IL-36 receptor; GPP, generalized pustular psoriasis; mDC, myeloid dendritic cell; Mo, monocytes; pDC, plasmacytoid dendritic cell; SEM, standard error of the mean.